AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Interferon alpha pdf12/19/2023 ElevenĬases of pancreatitis or symptomatic hyperlactatemia were observed, all in The 2 regimens showed similar tolerability although dose modifications forĬlinical and biological events were more frequent with peginterferon. Histologic activity diminished and fibrosis stabilized in virologic responders. Together, a decline in HCV-RNA of less than 2 log 10 from baselineĪnd detectable serum HCV-RNA at week 12 predicted 99% of treatment failures. Vs 43% for standard interferon, P = .88). Was not found in patients with HCV genotype 2, 3, or 5 (44% for peginterferon In patients with HCV genotype 1 or 4 infection (17% for peginterferon vs 6% This difference between the treatments was found Group than in the standard interferon group (27% vs 20%, P = .047). Results More patients had sustained virologic responses in the peginterferon Main Outcome Measures Sustained virologic response, defined by undetectable serum HCV-RNA Intervention Treatment with ribavirin 400 mg twice a day, orally, plus either peginterferonĪlfa-2b (1.5 μg/kg subcutaneous injection once a week) or standard interferonĪlfa-2b (3 million units of subcutaneous injection 3 times a week) for 48 HCV-RNA, abnormal liver histology, a CD4 cell count of at least 200 × 10 6/L, and stable plasma HIV-RNA. Patients Four hundred twelve HIV-HCV coinfected patients with detectable serum Were enrolled from February 2000 to February 2002 and followed up for 72 weeks. Vs standard interferon alfa-2b plus ribavirin in HIV-HCV coinfected patients.ĭesign and Settings A multicenter, randomized, parallel-group, open-label trial. Objective To study the safety and efficacy of peginterferon alfa-2b plus ribavirin Virologic efficacy and safety of the combination of peginterferon alfa-2bĪnd ribavirin in coinfected patients come from uncontrolled studies. Virus (HIV)–infected patients is a growing concern. Shared Decision Making and CommunicationĬontext Treatment of chronic hepatitis C virus (HCV) infection in human immunodeficiency.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience. Challenges in Clinical Electrocardiography.
0 Comments
Read More
Leave a Reply. |